Patents by Inventor John C. Cambier
John C. Cambier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220145253Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: January 27, 2022Publication date: May 12, 2022Applicants: NATIONAL JEWISH HEALTH, THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
-
Publication number: 20210355214Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.Type: ApplicationFiled: July 22, 2021Publication date: November 18, 2021Applicant: Nepenthe Bioscience LLCInventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
-
Patent number: 11078276Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.Type: GrantFiled: October 3, 2019Date of Patent: August 3, 2021Assignee: Nepenthe Bioscience LLCInventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
-
Publication number: 20200308545Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: June 15, 2020Publication date: October 1, 2020Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
-
Patent number: 10760055Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: GrantFiled: July 23, 2018Date of Patent: September 1, 2020Assignees: NATIONAL JEWISH HEALTH, THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
-
Publication number: 20200109198Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.Type: ApplicationFiled: October 3, 2019Publication date: April 9, 2020Applicant: Nepenthe Bioscience LLCInventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
-
Publication number: 20190024051Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: July 23, 2018Publication date: January 24, 2019Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
-
Patent number: 9796961Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: GrantFiled: October 8, 2014Date of Patent: October 24, 2017Assignees: The Regents of the University of Colorado, National Jewish HealthInventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
-
Publication number: 20160040129Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: October 2, 2015Publication date: February 11, 2016Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis Turner
-
Patent number: 9150831Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: GrantFiled: February 5, 2010Date of Patent: October 6, 2015Assignees: The Regents of the University of Colorado, National Jewish HealthInventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
-
Publication number: 20150240205Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: October 8, 2014Publication date: August 27, 2015Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis Turner
-
Patent number: 8883507Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: GrantFiled: October 18, 2006Date of Patent: November 11, 2014Assignees: The Regents of the University of Colorado, National Jewish HealthInventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
-
Publication number: 20120148566Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: ApplicationFiled: January 13, 2012Publication date: June 14, 2012Applicant: NATIONAL JEWISH HEALTHInventors: Barbara J. Vilen, John C. Cambier
-
Publication number: 20110212111Abstract: The present invention provides a MHC II associated protein, MPYS, and methods for using the same. In particular, the MHC II-associated protein of the present invention mediates apoptosis and influences the susceptibility to infectious diseases. The present invention also provides methods for treating clinical conditions, methods for identifying therapeutically useful compounds using such a protein, and methods for determining susceptibility to infectious disease.Type: ApplicationFiled: November 2, 2009Publication date: September 1, 2011Inventors: John C. Cambier, Lei Jin
-
Publication number: 20110097327Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: ApplicationFiled: September 16, 2010Publication date: April 28, 2011Applicant: NATIONAL JEWISH HEALTHInventors: Barbara J. Vilen, John C. Cambier
-
Publication number: 20100297763Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: February 5, 2010Publication date: November 25, 2010Applicant: TAIGA BIOTECHNOLOGIES, INC.Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
-
Patent number: 7825224Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: GrantFiled: July 2, 2007Date of Patent: November 2, 2010Assignee: National Jewish HealthInventors: Barbara J. Vilen, John C. Cambier
-
Publication number: 20030077284Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: ApplicationFiled: August 13, 2002Publication date: April 24, 2003Applicant: National Jewish Medical and Research CenterInventors: Barbara J. Vilen, John C. Cambier
-
Patent number: 6503509Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: GrantFiled: February 25, 2000Date of Patent: January 7, 2003Assignee: National Jewish Medical & Research CenterInventors: Barbara J. Vilen, John C. Cambier